PASG Relative Valuation
PASG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PASG is overvalued; if below, it's undervalued.
Historical Valuation
Passage Bio Inc (PASG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.50. The fair price of Passage Bio Inc (PASG) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：18.33
Fair
-1.42
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Passage Bio Inc. (PASG) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.05. The thresholds are as follows: Strongly Undervalued below -2.72, Undervalued between -2.72 and -1.34, Fairly Valued between 1.43 and -1.34, Overvalued between 1.43 and 2.82, and Strongly Overvalued above 2.82. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.19
EV/EBIT
Passage Bio Inc. (PASG) has a current EV/EBIT of -0.19. The 5-year average EV/EBIT is 0.06. The thresholds are as follows: Strongly Undervalued below -2.55, Undervalued between -2.55 and -1.24, Fairly Valued between 1.36 and -1.24, Overvalued between 1.36 and 2.66, and Strongly Overvalued above 2.66. The current Forward EV/EBIT of -0.19 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Passage Bio Inc. (PASG) has a current PS of 0.00. The 5-year average PS is 1.65. The thresholds are as follows: Strongly Undervalued below -10.36, Undervalued between -10.36 and -4.36, Fairly Valued between 7.65 and -4.36, Overvalued between 7.65 and 13.66, and Strongly Overvalued above 13.66. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Passage Bio Inc. (PASG) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.22. The thresholds are as follows: Strongly Undervalued below -4.96, Undervalued between -4.96 and -3.09, Fairly Valued between 0.65 and -3.09, Overvalued between 0.65 and 2.53, and Strongly Overvalued above 2.53. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.96
P/FCF
Passage Bio Inc. (PASG) has a current P/FCF of -0.96. The 5-year average P/FCF is -1.35. The thresholds are as follows: Strongly Undervalued below -5.20, Undervalued between -5.20 and -3.28, Fairly Valued between 0.57 and -3.28, Overvalued between 0.57 and 2.49, and Strongly Overvalued above 2.49. The current Forward P/FCF of -0.96 falls within the Historic Trend Line -Fairly Valued range.
Passage Bio Inc (PASG) has a current Price-to-Book (P/B) ratio of 1.19. Compared to its 3-year average P/B ratio of 0.51 , the current P/B ratio is approximately 136.28% higher. Relative to its 5-year average P/B ratio of 0.78, the current P/B ratio is about 52.77% higher. Passage Bio Inc (PASG) has a Forward Free Cash Flow (FCF) yield of approximately -90.12%. Compared to its 3-year average FCF yield of -162.54%, the current FCF yield is approximately -44.55% lower. Relative to its 5-year average FCF yield of -128.22% , the current FCF yield is about -29.71% lower.
1.19
P/B
Median3y
0.51
Median5y
0.78
-90.12
FCF Yield
Median3y
-162.54
Median5y
-128.22
Competitors Valuation Multiple
The average P/S ratio for PASG's competitors is 4.71, providing a benchmark for relative valuation. Passage Bio Inc Corp (PASG) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PASG increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PASG in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Passage Bio Inc (PASG) currently overvalued or undervalued?
Passage Bio Inc (PASG) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.50. The fair price of Passage Bio Inc (PASG) is between NaN to NaN according to relative valuation methord.
What is Passage Bio Inc (PASG) fair value?
PASG's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Passage Bio Inc (PASG) is between NaN to NaN according to relative valuation methord.
How does PASG's valuation metrics compare to the industry average?
The average P/S ratio for PASG's competitors is 4.71, providing a benchmark for relative valuation. Passage Bio Inc Corp (PASG) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Passage Bio Inc (PASG) as of Jan 08 2026?
As of Jan 08 2026, Passage Bio Inc (PASG) has a P/B ratio of 1.19. This indicates that the market values PASG at 1.19 times its book value.
What is the current FCF Yield for Passage Bio Inc (PASG) as of Jan 08 2026?
As of Jan 08 2026, Passage Bio Inc (PASG) has a FCF Yield of -90.12%. This means that for every dollar of Passage Bio Inc’s market capitalization, the company generates -90.12 cents in free cash flow.
What is the current Forward P/E ratio for Passage Bio Inc (PASG) as of Jan 08 2026?
As of Jan 08 2026, Passage Bio Inc (PASG) has a Forward P/E ratio of -1.42. This means the market is willing to pay $-1.42 for every dollar of Passage Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Passage Bio Inc (PASG) as of Jan 08 2026?
As of Jan 08 2026, Passage Bio Inc (PASG) has a Forward P/S ratio of 0.00. This means the market is valuing PASG at $0.00 for every dollar of expected revenue over the next 12 months.